How long should I wait before switching from dofetilide (Tikosyn) to amiodarone?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: November 19, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Switching from Tikosyn (Dofetilide) to Amiodarone: Washout Period

You should wait at least 2 days after discontinuing dofetilide before starting amiodarone. This washout period allows for adequate clearance of dofetilide to minimize the risk of additive QT prolongation and proarrhythmic effects when transitioning between these Class III antiarrhythmic agents.

Rationale for the 2-Day Washout

The FDA-approved prescribing information for Tikosyn (dofetilide) explicitly states: "If TIKOSYN needs to be discontinued to allow dosing of other potentially interacting drug(s), a washout period of at least two days should be followed before starting the other drug(s)" 111. This recommendation is based on dofetilide's pharmacokinetic profile and the need to minimize overlapping QT-prolonging effects.

Key Pharmacokinetic Considerations:

  • Dofetilide elimination half-life: Approximately 10 hours in patients with normal renal function
  • Time to steady-state clearance: After 2 days (approximately 5 half-lives), over 95% of dofetilide will be eliminated from the body
  • Renal excretion: Dofetilide is primarily eliminated by the kidneys, so patients with impaired renal function may require longer washout periods

Clinical Implementation Algorithm

Step 1: Discontinue Dofetilide

  • Stop all dofetilide doses immediately
  • Document the last dose timing and QTc interval

Step 2: Monitor During Washout Period

  • Minimum 2-day waiting period before initiating amiodarone
  • Monitor ECG and QTc interval during this period
  • Ensure QTc returns toward baseline (ideally <500 msec)
  • Consider rate control agents if needed for symptomatic atrial fibrillation during the washout

Step 3: Assess Renal Function

  • If creatinine clearance is <60 mL/min, consider extending the washout period to 3-4 days due to prolonged dofetilide elimination
  • Verify electrolytes (potassium and magnesium) are within normal range before starting amiodarone

Step 4: Initiate Amiodarone

After the 2-day washout (or longer if renal impairment exists):

  • Loading regimen: 600-800 mg daily in divided doses until 10 g total load achieved 222
  • Alternative loading: 400-600 mg daily over 2-4 weeks 34
  • Maintenance: 200-400 mg daily 33

Important Safety Considerations

Why This Direction is Safer Than the Reverse

The transition from dofetilide to amiodarone is considerably safer and simpler than the reverse direction. When switching FROM amiodarone TO dofetilide, FDA guidelines mandate waiting at least 3 months OR until amiodarone plasma levels fall below 0.3 mcg/mL 111. This is due to amiodarone's:

  • Extremely long elimination half-life (26-107 days for oral dosing) 56
  • Extensive tissue accumulation
  • Unpredictable pharmacokinetics

Recent research suggests this 3-month washout may be shortened in select patients with implantable cardioverter-defibrillators under close monitoring 78, but the standard remains 3 months.

Monitoring Requirements During Transition

During the 2-day washout:

  • Daily ECG with QTc measurement
  • Serum potassium and magnesium levels (correct if low)
  • Symptom assessment for arrhythmia recurrence

After starting amiodarone:

  • Baseline ECG, liver function tests, thyroid function tests, chest X-ray 9
  • Monitor for bradycardia and QT prolongation in first 24-48 hours
  • Follow-up thyroid and liver function every 6 months 9
  • Annual chest radiograph for pulmonary toxicity surveillance 22

Common Pitfalls to Avoid

  1. Do not overlap the medications: Both drugs prolong the QT interval through potassium channel blockade, creating additive risk for torsades de pointes
  2. Do not rush the transition in renal impairment: Patients with reduced creatinine clearance need longer washout periods
  3. Do not forget electrolyte optimization: Hypokalemia and hypomagnesemia significantly increase proarrhythmic risk with both agents
  4. Do not initiate amiodarone outpatient without baseline testing: Obtain baseline thyroid, liver, and pulmonary function before starting

Special Clinical Scenarios

Urgent Need for Rhythm Control

If immediate rhythm control is needed during the 2-day washout:

  • Use rate-control agents (beta-blockers, calcium channel blockers, digoxin) 33
  • Consider electrical cardioversion if hemodynamically unstable
  • Do NOT start amiodarone early to avoid overlapping QT effects

Patients with Structural Heart Disease

Amiodarone is particularly appropriate for patients with:

  • Heart failure (LVEF <40%) 10109
  • Significant left ventricular hypertrophy
  • Coronary artery disease 1010

These patients should still observe the 2-day washout but may benefit most from the transition given amiodarone's superior safety profile in structural heart disease compared to dofetilide.

References

Guideline

amiodarone: guidelines for use and monitoring.

American family physician, 2003

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.